475 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Hyaluronidase Fihj Plasma Cell Myeloma	Massachusetts General Hospital	P4	BBB (77)
Cyclosporin A Plasma Cell Myeloma	Seoul National University Hospital	P3	BBB (74)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Plasma Cell Myeloma	University of Birmingham	P4	BBB (72)
Adriamycin Plasma Cell Myeloma	GlaxoSmithKline	P4	BB (70)
Cis-Diamminedichloroplatinum Ii Plasma Cell Myeloma	Janssen Research & Development, LLC	P4	BB (70)
Cytarabine Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	BB (70)
Prednisone Plasma Cell Myeloma	GlaxoSmithKline	P4	BB (70)
qls32015 Plasma Cell Myeloma	Qilu Pharmaceutical Co., Ltd.	P3	BB (70)
Bortezomib Plasma Cell Myeloma	Universitätsklinikum Hamburg-Eppendorf	P4	BB (69)
Carfilzomib Plasma Cell Myeloma	National Cancer Institute (NCI)	P4	BB (69)
Cyclophosphamide Plasma Cell Myeloma	Fred Hutchinson Cancer Center	P4	BB (69)
Daratumumab Plasma Cell Myeloma	Janssen Research & Development, LLC	P4	BB (69)
Dexasone Plasma Cell Myeloma	Universitätsklinikum Hamburg-Eppendorf	P4	BB (69)
Lenalidomide Plasma Cell Myeloma	Universitätsklinikum Hamburg-Eppendorf	P4	BB (69)
Nivestim Plasma Cell Myeloma	Janssen Research & Development, LLC	P4	BB (69)
Pomalidomide Plasma Cell Myeloma	National Cancer Institute (NCI)	P4	BB (69)
Tacrolimus Plasma Cell Myeloma	Thomas Jefferson University	P3	BB (69)
Carboplatin Plasma Cell Myeloma	Andrew Hantel, MD	P2	BB (68)
Isatuximab Plasma Cell Myeloma	Universitätsklinikum Hamburg-Eppendorf	P4	BB (68)
Methotrexate Plasma Cell Myeloma	Poseida Therapeutics, Inc.	P3	BB (68)
Sargramostim Plasma Cell Myeloma	Roswell Park Cancer Institute	P3	BB (68)
Thalidomide Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P4	BB (68)
Busulfanum Plasma Cell Myeloma	SCRI Development Innovations, LLC	P4	BB (67)
Linvoseltamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (67)
Melphalan Plasma Cell Myeloma	Dana-Farber Cancer Institute	P4	BB (67)
Talquetamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (67)
Teclistamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (67)
Diphenhydramine Plasma Cell Myeloma	SCRI Development Innovations, LLC	P4	BB (66)
Elranatamab Plasma Cell Myeloma	Anne Louise Tølbøll Sørensen	P4	BB (66)
Fludarabine Plasma Cell Myeloma	Fred Hutchinson Cancer Center	P4	BB (66)
Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P3	BB (66)
Mezigdomide Plasma Cell Myeloma	SCRI Development Innovations, LLC	P4	BB (66)
Etoposide Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	BB (65)
Elotuzumab Plasma Cell Myeloma	Hoffmann-La Roche	P3	BB (64)
Gm-Csf Plasma Cell Myeloma	David Avigan	P3	BB (64)
Human Immunoglobulins Plasma Cell Myeloma	Monash University	P2/3	BB (64)
Leflunomide Plasma Cell Myeloma	City of Hope Medical Center	P2	BB (64)
Anti-Bcma/Anti-Cd3 T-Cell Engaging Bispecific Antibody Abbv-383 Plasma Cell Myeloma	Universitätsklinikum Hamburg-Eppendorf	P3	B (63)
Anti-Bcma Car-T Cells Plasma Cell Myeloma	Thomas Martin, MD	P3	B (63)
Cart-Ddbcma Plasma Cell Myeloma	PETHEMA Foundation	P3	B (63)
Cevostamab Plasma Cell Myeloma	Hoffmann-La Roche	P3	B (63)
CM336 Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P3	B (63)
Iberdomide Plasma Cell Myeloma	Dana-Farber Cancer Institute	P3	B (63)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Plasma Cell Myeloma	Sanofi	P2	B (63)
Lomustine Plasma Cell Myeloma	Actuate Therapeutics Inc.	P3	B (63)
Daratumumab-Hyaluronidase Plasma Cell Myeloma	PrECOG, LLC.	P3	B (62)
Montelukast Plasma Cell Myeloma	Emory University	P4	B (62)
Ranitidine Plasma Cell Myeloma	Hoffmann-La Roche	P3	B (62)
sg301 Plasma Cell Myeloma	Hangzhou Sumgen Biotech Co., Ltd.	P3	B (62)
Siltuximab Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P3	B (62)

Showing 1 to 50 of 475 assets

PreviousPage 1 of 10Next